170 related articles for article (PubMed ID: 24820058)
21. Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer.
van Soest RJ; de Morrée ES; Kweldam CF; de Ridder CMA; Wiemer EAC; Mathijssen RHJ; de Wit R; van Weerden WM
Eur Urol; 2015 Jun; 67(6):981-985. PubMed ID: 25484141
[TBL] [Abstract][Full Text] [Related]
22. Perspectives on the current and emerging chemical androgen receptor antagonists for the treatment of prostate cancer.
Dellis AE; Papatsoris AG
Expert Opin Pharmacother; 2019 Feb; 20(2):163-172. PubMed ID: 30462924
[TBL] [Abstract][Full Text] [Related]
23. Enzalutamide as a second generation antiandrogen for treatment of advanced prostate cancer.
Semenas J; Dizeyi N; Persson JL
Drug Des Devel Ther; 2013; 7():875-81. PubMed ID: 24009414
[TBL] [Abstract][Full Text] [Related]
24. Enzalutamide: A Review in Castration-Resistant Prostate Cancer.
Scott LJ
Drugs; 2018 Dec; 78(18):1913-1924. PubMed ID: 30535926
[TBL] [Abstract][Full Text] [Related]
25. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
[TBL] [Abstract][Full Text] [Related]
26. Safety and effectiveness of enzalutamide in men with metastatic, castration-resistant prostate cancer.
Graff JN; Gordon MJ; Beer TM
Expert Opin Pharmacother; 2015 Apr; 16(5):749-54. PubMed ID: 25687355
[TBL] [Abstract][Full Text] [Related]
27. Enzalutamide, a second generation androgen receptor antagonist: development and clinical applications in prostate cancer.
Menon MP; Higano CS
Curr Oncol Rep; 2013 Apr; 15(2):69-75. PubMed ID: 23341368
[TBL] [Abstract][Full Text] [Related]
28. Combination therapy with a second-generation androgen receptor antagonist and a metastasis vaccine improves survival in a spontaneous prostate cancer model.
Ardiani A; Farsaci B; Rogers CJ; Protter A; Guo Z; King TH; Apelian D; Hodge JW
Clin Cancer Res; 2013 Nov; 19(22):6205-18. PubMed ID: 24048332
[TBL] [Abstract][Full Text] [Related]
29. Alterations of androgen receptor-regulated enhancer RNAs (eRNAs) contribute to enzalutamide resistance in castration-resistant prostate cancer.
Zhao J; Zhao Y; Wang L; Zhang J; Karnes RJ; Kohli M; Wang G; Huang H
Oncotarget; 2016 Jun; 7(25):38551-38565. PubMed ID: 27221037
[TBL] [Abstract][Full Text] [Related]
30.
Özgür E; Celik AI; Darendeliler E; Gezer U
Anticancer Res; 2017 Jul; 37(7):3631-3637. PubMed ID: 28668854
[TBL] [Abstract][Full Text] [Related]
31. The clinical benefit of sequential therapy with androgen receptor axis-targeted agents alone in patients with castration-resistant prostate cancer: A propensity score-matched comparison study.
Naito Y; Kato M; Kawanishi H; Yuguchi Y; Yuba T; Ishikawa T; Hattori K; Yamamoto A; Sano T; Matsukawa Y; Kimura T; Nishikimi T; Hattori R; Tsuzuki T; Gotoh M
Prostate; 2020 Nov; 80(15):1373-1380. PubMed ID: 32914895
[TBL] [Abstract][Full Text] [Related]
32. Enzalutamide: a novel anti-androgen with prolonged survival rate in CRPC patients.
Dhingra R; Sharma T; Singh S; Sharma S; Tomar P; Malhotra M; Bhardwaj TR
Mini Rev Med Chem; 2013 Aug; 13(10):1475-86. PubMed ID: 23701654
[TBL] [Abstract][Full Text] [Related]
33. Restoration of the cellular secretory milieu overrides androgen dependence of in vivo generated castration resistant prostate cancer cells overexpressing the androgen receptor.
Patki M; Huang Y; Ratnam M
Biochem Biophys Res Commun; 2016 Jul; 476(2):69-74. PubMed ID: 27179779
[TBL] [Abstract][Full Text] [Related]
34. Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: study protocol for a multicenter randomized phase II trial (the OCUU-CRPC study).
Iguchi T; Tamada S; Kato M; Yasuda S; Yamasaki T; Nakatani T
BMC Cancer; 2019 Apr; 19(1):339. PubMed ID: 30971225
[TBL] [Abstract][Full Text] [Related]
35. Combined N-terminal androgen receptor and autophagy inhibition increases the antitumor effect in enzalutamide sensitive and enzalutamide resistant prostate cancer cells.
Kranzbühler B; Salemi S; Mortezavi A; Sulser T; Eberli D
Prostate; 2019 Feb; 79(2):206-214. PubMed ID: 30345525
[TBL] [Abstract][Full Text] [Related]
36. A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509.
Joseph JD; Lu N; Qian J; Sensintaffar J; Shao G; Brigham D; Moon M; Maneval EC; Chen I; Darimont B; Hager JH
Cancer Discov; 2013 Sep; 3(9):1020-9. PubMed ID: 23779130
[TBL] [Abstract][Full Text] [Related]
37. Drug Resistance of Enzalutamide in CRPC.
Chen X; Lu J; Xia L; Li G
Curr Drug Targets; 2018; 19(6):613-620. PubMed ID: 28413979
[TBL] [Abstract][Full Text] [Related]
38. Dual targeting of the androgen receptor and hypoxia-inducible factor 1α pathways synergistically inhibits castration-resistant prostate cancer cells.
Fernandez EV; Reece KM; Ley AM; Troutman SM; Sissung TM; Price DK; Chau CH; Figg WD
Mol Pharmacol; 2015 Jun; 87(6):1006-12. PubMed ID: 25829060
[TBL] [Abstract][Full Text] [Related]
39. Identification of mechanisms of resistance to treatment with abiraterone acetate or enzalutamide in patients with castration-resistant prostate cancer (CRPC).
Pal SK; Patel J; He M; Foulk B; Kraft K; Smirnov DA; Twardowski P; Kortylewski M; Bhargava V; Jones JO
Cancer; 2018 Mar; 124(6):1216-1224. PubMed ID: 29266182
[TBL] [Abstract][Full Text] [Related]
40. Resistance emerges to second-generation antiandrogens in prostate cancer.
Nelson WG; Yegnasubramanian S
Cancer Discov; 2013 Sep; 3(9):971-4. PubMed ID: 24019330
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]